Save time and jump to the most important pieces.
Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provided a business update and reported financial results for the third quarter ended September 30, 2024. "We are pleased to share the progress made in the third quarter of 2024, highlighted by the advancement of our robust development portfolio centered ar
BASKING RIDGE, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details with dial-in options. To
Phase 2b ASCEND trial top-line data remains on track to be reported in fourth quarter of 2024 Available cash projected to fund current operations into early 2026 and all active studies through to data Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provided a business update and reported financial results for the second quarter ended June 30, 2024. "The second quarter generated strong momentum for Lisa
10-Q - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
424B5 - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
HC Wainwright & Co. analyst Joseph Pantginis reiterates Lisata Therapeutics (NASDAQ:LSTA) with a Buy and maintains $15 price target.
Haystack Oncology, a Quest Diagnostics Inc. (NYSE:DGX) company, announced a research collaboration with Lisata Therapeutics Inc. (NASDAQ:LSTA). Haystack Oncology developed Haystack MRD, a next-generation tumor-informed approach to measure minimal residual disease. Haystack MRD uses an error-corrected ctDNA technology to detect down to one ctDNA molecule in a million normal DNA molecules. Lisata Therapeutics is a clinical-stage pharmaceutical company developing innovative therapies for advanced solid tumors. Under the agreement, Lisata will deploy the Haystack MRD technology to detect circulating tumor DNA (ctDNA) in a clinical study evaluating certepetide plus chemotherapy as an inv
BASKING RIDGE, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced it has entered into a sponsored research agreement with the University of Cincinnati to investigate Lisata's novel cyclic peptide product candidate, certepetide, in combination with bevacizumab (a VEGF inhibitor) in a preclinical animal model for the treatment of endometriosis. Bevacizumab has previously demonstrated efficacy in treating endometriosis; however, the required dosage levels are associated with systemic side effects, limiting
BASKING RIDGE, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that Erkki Ruoslahti, M.D., Ph.D., has decided to retire from its Board of Directors effective today, July 11, 2023. Dr. Ruoslahti will remain associated with the Company, however, in a scientific advisory position. Dr. Ruoslahti cites the arduous requirements of international travel (he currently resides in Sweden) as well as his confidence in both the progress made with the Company's lead asset, LSTA1, and the
Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provided a business update and reported financial results for the third quarter ended September 30, 2024. "We are pleased to share the progress made in the third quarter of 2024, highlighted by the advancement of our robust development portfolio centered ar
BASKING RIDGE, N.J. and HELSINKI, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and Valo Therapeutics Oy ("ValoTx"), a private company developing novel, adaptable immunotherapies for the treatment of cancer, are pleased to announce a preclinical research collaboration to investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's innovative platform technology, PeptiCRAd, and a checkpoint inhibitor in a melanoma mouse model. Under the agreement, ValoTx will be conducting the researc
BASKING RIDGE, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details with dial-in options. To
4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)